3 New Strong Buy Ratings from Top-Rated Analysts: 04/04/2025

Not all stocks are scared of tariffs. Here are three brand-new Strong Buy alerts, all sourced from our Strong Buy Stocks from Top Wall Street Analysts screener:

• Why Catalyst Pharmaceuticals (NASDAQ: CPRX) could see 30%+ upside in the coming year 
• Ardent Health Partners (NYSE: ARDT) is trending after its IPO 
• Why Sprouts Farmers Market (NASDAQ: SFM) earns the coveted Stock of the Week status

P.S. Want more alerts like this daily? Try WallStreetZen Premium.

1. Catalyst Pharmaceuticals (NASDAQ: CPRX)

Catalyst Pharmaceuticals focuses on neurological and neuromuscular treatments. Strong revenue growth and a healthy checkbook make it an appealing choice in terms of growth, but a recent pullback has made it quite attractive in terms of value as well. What’s more, a recently announced legal victory, the business has secured a key source of growth from competitors.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $24.69  — get current quote > 

Max 1-year forecast: $36.00 

Why we’re watching:

• With 3 Strong Buy ratings and 2 Buy ratings, it’s clear that equity researchers are quite bullish on Catalyst Pharmaceuticals. Notably, the stock has no Hold, Sell, or Strong Sell ratings. See the ratings
• In addition, the average 12-month price forecast for CPRX currently sits at $33.20 — a figure that implies a hefty 34.47% upside.
• The Street-high $36 price target comes from Truist Securities researcher Joon Lee (a top 2% rated analyst). However, readers should note that Lee has not updated his coverage since November.
• More recently, Baird’s Joel Beatty (a top 26% rated analyst) reiterated a Buy rating on the stock, and maintained a $32 price target.
• Back in January, the company scored a huge legal win over competitor Teva Pharmaceutical Industries (NYSE: TEVA) — with the ruling preventing a competing, generic product from entering the market. 
• With an overall Zen Rating of A, CPRX belongs to a class of equities that have provided an average annual return of 32.52% for more than two decades. Interestingly enough, the average price target set by Wall Street researchers is right around this mark in terms of upside.
• Catalyst Pharmaceuticals stock carries an overall Zen Rating of A, and ranks in the top 2% of stocks according to our proprietary quant rating model.
• Value and Financials are where CPRX shines — with a P/E ratio of 17.89x and a PEG ratio of 0.83x, it’s little surprise that it ranks in the top 3% of stocks in the first category. As for Financials, the outlook is even better, as CPRX ranks in the top 2% in that regard.. (See all 7 Zen Component Grades here >)

2. Ardent Health Partners (NYSE: ARDT) 

Fresh off its IPO, Ardent Health Partners is still flying under the radar despite being one of the largest for-profit hospital operators in the U.S. With 30 hospitals and over 200 care sites across six states, Ardent is positioned at the intersection of regional healthcare demand and efficient, scalable operations. The price of ARDT shares has fallen significantly since they’ve gone public — and present prices present a rather attractive entry point.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $13.14 — get current quote > 

Max 1-year forecast: $25.00 

Why we’re watching:

• Ardent Healthcare is currently tracked by 9 Wall Street analysts, and has 5 Strong Buy ratings, 2 Buy ratings, and 2 Hold ratings. See the ratings.
• On March 26, Stephens & Co. researcher Scott Fidel (a top 9% rated analyst) doubled down on a previously set Strong Buy rating, and kept a $22 price target on ARDT shares.
• The average 12-month price forecast for Ardent Health stock, which is slightly lower than Fidel’s at $21.78, implies an impressive 65.49% upside — so it’s clear that the Street is quite bullish.  
• Our proprietary quant rating system is in agreement, as it currently rates ARDT an A in terms of its Zen Rating, placing it in the top 5% of equities overall.
• Ardent Health is the 2nd best-rated stock in the entire Medical Care Facility industry (although it enjoys better analyst coverage, as well as a higher projected upside, when compared to the number-one rated stock in the industry).
• The stock ranks in the top 1% according to its Value Component Grade rating, and is currently trading at an enticing price-to-earnings growth (PEG) ratio of 0.73x, and a P/E of just 8.28x. (See all 7 Zen Component Grades here >)

3. Sprouts Farmers Market (NASDAQ: SFM)

Our last entry for today is also our Stock of the Week. Sprouts Farmers Market is well-positioned to benefit from a healthy appetite (pun intended) for healthy, fresh, organic, farm-to-table produce. In addition, with a trade war brewing, gaining exposure to a company whose operations are tariff-proof and whose products fall under non-discretionary spending seems like a prudent choice.

Zen Rating: B (Buy) — see full analysis >  

Recent Price: $151.51  — get current quote > 

Max 1-year forecast: $200.00 

Why we’re watching:

• Sprouts Farmers Market is our Stock of the Week. Our Editor-in-Chief, Steve Reitmeister, highlighted SFM’s key strengths in a Monday article. You ought to give it a read — but we’ll provide the Cliff Notes version here.
• Over the past 5 years EPS has impressed investors with a streak of 20 straight earnings that has led to a 9X increase in the share price.
• The streak doesn’t appear like it will end any time soon — last quarter’s 7.5% beat set off a chain reaction of higher earnings estimates for this year and next by about 10%.
• So,  why did estimates go up more than the size of the beat? Steve posits that it is because there is clearly earnings momentum in their business model that points to an even brighter future.
• At present, the Street-high price target of $200 is issued by Kate McShane of Goldman Sachs (a top 14% rated analyst)
• SFM carries an overall Zen Rating of B — but qualifies in the top 10% of stocks on the whole.  
• Sprouts Farmers Market stock also boasts an impressive and wide array of strong Component Grade ratings — top 7% in Artificial Intelligence and top 8% in Financials being chief among them. SFM also ranks in the top 10% in another category — but you’ll have to take a look at Steve’s article to find out which one. (See all 7 Zen Component Grades here >)

What to Do Next?

• 8 Stock Lists You Need Now >
• See All “A” Rated Stocks with +32.52% Average Annual Return > 
• 4 Step Process to Find More 100%+ Stock Winners >

Want to get in touch? Email us at news@wallstreetzen.com.